PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.85%
Revenue growth at 50-75% of MRVL's 15.39%. Martin Whitman would worry about competitiveness or product relevance.
7.13%
Gross profit growth at 50-75% of MRVL's 10.75%. Martin Whitman would question if cost structure or brand is lagging.
33.59%
EBIT growth below 50% of MRVL's 83.20%. Michael Burry would suspect deeper competitive or cost structure issues.
33.59%
Operating income growth under 50% of MRVL's 83.20%. Michael Burry would be concerned about deeper cost or sales issues.
23.11%
Net income growth under 50% of MRVL's 66.85%. Michael Burry would suspect the firm is falling well behind a key competitor.
25.00%
EPS growth under 50% of MRVL's 61.54%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
25.00%
Diluted EPS growth under 50% of MRVL's 75.00%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.76%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.55%
Reduced diluted shares while MRVL is at 0.11%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
0.90%
Maintaining or increasing dividends while MRVL cut them. John Neff might see a strong edge in shareholder returns.
68.26%
OCF growth at 50-75% of MRVL's 104.86%. Martin Whitman would question if the firm lags in monetizing sales effectively.
981.22%
FCF growth above 1.5x MRVL's 138.11%. David Dodd would verify if the firm’s strategic investments yield superior returns.
80.86%
10Y revenue/share CAGR under 50% of MRVL's 348.15%. Michael Burry would suspect a lasting competitive disadvantage.
9.92%
5Y revenue/share CAGR under 50% of MRVL's 46.43%. Michael Burry would suspect a significant competitive gap or product weakness.
24.13%
3Y revenue/share CAGR at 75-90% of MRVL's 28.21%. Bill Ackman would expect new product strategies to close the gap.
1671.53%
10Y OCF/share CAGR above 1.5x MRVL's 470.87%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
253.37%
Positive OCF/share growth while MRVL is negative. John Neff might see a comparative advantage in operational cash viability.
-23.97%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
1458.15%
Net income/share CAGR above 1.5x MRVL's 794.09% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
80.02%
5Y net income/share CAGR similar to MRVL's 80.86%. Walter Schloss might see both on parallel mid-term trajectories.
39.06%
Positive short-term CAGR while MRVL is negative. John Neff would see a clear advantage in near-term profit trajectory.
256.93%
10Y equity/share CAGR above 1.5x MRVL's 117.01%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
62.64%
5Y equity/share CAGR 1.25-1.5x MRVL's 44.91%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
48.19%
3Y equity/share CAGR above 1.5x MRVL's 12.75%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.06%
AR growth well above MRVL's 8.32%. Michael Burry fears inflated revenue or higher default risk in the near future.
0.54%
Inventory shrinking or stable vs. MRVL's 13.45%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
2.55%
Similar asset growth to MRVL's 2.76%. Walter Schloss finds parallel expansions or investment rates.
4.36%
BV/share growth above 1.5x MRVL's 2.09%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-3.79%
We’re deleveraging while MRVL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
2.58%
R&D growth drastically higher vs. MRVL's 1.25%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-4.74%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.